RT Journal Article
T1 Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology.
A1 Calleja, José L
A1 Rivera-Esteban, Jesús
A1 Aller, Rocío
A1 Hernández-Conde, Marta
A1 Abad, Javier
A1 Pericàs, Juan M
A1 Benito, Hugo G
A1 Serra, Miguel A
A1 Escudero, Amparo
A1 Ampuero, Javier
A1 Lucena, Ana
A1 Sánchez, Yolanda
A1 Arias-Loste, María T
A1 Iruzubieta, Paula
A1 Romero-Gómez, Manuel
A1 Augustin, Salvador
A1 Crespo, Javier
K1 hepatic fibrosis
K1 liver biopsy
K1 non-alcoholic steatohepatitis
K1 transient elastography
AB Non-alcoholic fatty liver disease (NAFLD) has become a major public health problem, but the prevalence of fibrosis associated with non-alcoholic steatohepatitis (NASH) is largely unknown in the general population. This study aimed to provide an updated estimation of the prevalence of NASH fibrosis in Spain. This was an observational, retrospective, cross-sectional, population-based study with merged data from two Spanish datasets: a large (N = 12 246) population-based cohort (ETHON), including transient elastography (TE) data, and a contemporary multi-centric biopsy-proven NASH cohort with paired TE data from tertiary centres (N = 501). Prevalence for each NASH fibrosis stage was estimated by crossing TE data from ETHON dataset with histology data from the biopsy-proven cohort. From the patients with valid TE in ETHON dataset (N = 11 440), 5.61% (95% confidence interval [95% CI]: 2.53-11.97) had a liver stiffness measurement (LSM) ≥ 8 kPa. The proportion attributable to NAFLD (using clinical variables and Controlled Attenuation Parameter) was 57.3% and thus, the estimated prevalence of population with LSM ≥ 8 kPa because of NAFLD was 3.21% (95% CI 1.13-8.75). In the biopsy-proven NASH cohort, 389 patients had LSM ≥ 8 kPa. Among these, 37% did not have significant fibrosis (F2-4). The estimated prevalence of NASH F2-3 and cirrhosis in Spain's adult population were 1.33% (95% CI 0.29-5.98) and 0.70% (95% CI 0.10-4.95) respectively. These estimations provide an accurate picture of the current prevalence of NASH-related fibrosis in Spain and can serve as reference point for dimensioning the therapeutic efforts that will be required as NASH therapies become available.
YR 2022
FD 2022-06-07
LK http://hdl.handle.net/10668/20007
UL http://hdl.handle.net/10668/20007
LA en
DS RISalud
RD Apr 5, 2025